Skip to content
Open access

When Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantification and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy

Oct 2026 · medRxiv · 0 citations
Medicine

TL;DR

Centiloid quantification was robust across pipelines before and after ATT initiation, yielding clearance rates consistent with clinical trials, However, quantitative and visual assessments were markedly discordant after ATT, warranting cautious interpretation of post-ATT Centiloid values.

Abstract

Amyloid-targeting therapies (ATTs) substantially reduce amyloid PET signal and slow clinical decline in early symptomatic Alzheimer disease. As ATTs enter clinical practice, PET may assess target engagement and guide treatment management, but there is no consensus on how to measure treatment-related amyloid clearance (TRAC). We compared Centiloid quantification across pipelines and visual reads for interpreting pre- and post-ATT amyloid PET. Methods: We analyzed 18F-florbetapir or 18F-florbetaben PET from 101 patients treated with lecanemab or donanemab: 88 pre-ATT and 54 post-ATT scans, including 41 paired scans. Centiloids were derived using FDA-cleared MIMneuro and two research pipelines (rPOP, CapAIBL) and compared using intraclass correlation coefficients (ICC). Clearance rates were estimated using linear mixed-effects models. Full TRAC was defined on post-ATT scans quantitatively (<11 Centiloids) or based on visual interpretation by three expert readers. Results: Treated patients were 74+/-7 years old; 57% were female, 59% were apolipoprotein E4 carriers, and 78% had mild cognitive impairment (22% mild dementia). Centiloid agreement between pipelines was equally high pre- and post-ATT (both ICCs=0.90). Among paired scans (mean treatment duration, 16.7 +/- 4.6 months), clearance estimates were similar across pipelines and greater with donanemab (n=15 patients; between -62 and -60 Centiloids/year depending on the pipeline) than lecanemab (n=26; -38 to -36 Centiloids/year; all Ps<0.005). Among 54 post-ATT scans, between 44% and 57% were <11 Centiloids depending on pipeline, with 20 (37%) meeting this criterion across all three pipelines. In contrast, only 11% to 19% were visually negative across readers, with 4 (7%) unanimously read as negative. Of the 20 post-ATT scans <11 Centiloids across all pipelines, 13 (65%) were considered positive by all readers, commonly with residual occipital binding. Conclusion: Centiloid quantification was robust across pipelines before and after ATT initiation, yielding clearance rates consistent with clinical trials. However, quantitative and visual assessments were markedly discordant after ATT, with an unusually high proportion of scans <11 Centiloids remaining visually positive, warranting cautious interpretation of post-ATT Centiloid values. Larger studies should assess the clinical relevance of these findings and further develop robust approaches to establish full TRAC.

Read PDF

Similar papers

Open access Oct 2026

Regional amyloid‐PET clearance dynamics and anti‐Aβ monoclonal antibody therapy: a preliminary real‐world study

Abstract INTRODUCTION Amyloid positron emission tomography (PET) is the reference biomarker for treatment target engagement in anti‐amyloid beta (Aβ) therapies in early symptomatic Alzheimer's disease (AD), yet global metrics may mask a regional heterogeneity of amyloid clearance. METHODS We report real‐world longitudi...

A. Ghirelli, G. Cecchetti, E. Spinelli et al. · 0 citations
Open access Nov 2026

Comparison of [18F]-florbetapir PET visual interpretation and quantitation to detect amyloid pathology at the community level

Introduction In research and clinical trial applications, [18F]-florbetapir positron emission tomography (PET) imaging data are commonly evaluated with quantitation-based approaches. In clinical practice, scans are primarily interpreted visually by nuclear medicine physicians or radiologists (community readers), often...

Jian Wang, L. Iaccarino, A. Arora et al. · 0 citations
Nov 2026

Cross-platform Comparison of Quantitative Florbetapir Amyloid PET Using MIMneuro and Neurophet SCALE PET.

BACKGROUND Quantitative amyloid PET is increasingly used in clinical practice, but the interchangeability of quantification software remains uncertain. We compared quantitative amyloid PET measurements, diagnostic performance, and platform-specific thresholds between two FDA-cleared software packages, MIMneuro and Neur...

Mehmet Aksakal, Hisham Alfarra, C. Watt et al. · 0 citations
Open access Oct 2026

Spatial patterns of amyloid clearance after donanemab: A preliminary 12‐month real‐world amyloid PET study in Japanese patients with early Alzheimer's disease

Abstract Introduction The regional pattern of amyloid clearance during donanemab treatment in routine practice is poorly characterized. Methods We analyzed amyloid positron emission tomography (Centiloid, regional standardized uptake value ratio, visual reads) at baseline and 12 months in 18 donanemab‐treated patients...

Yuki Kujuro, Marina Saito, Manami Maruko et al. · 0 citations
Oct 2026

PET-based evaluation of short-term amyloid-β clearance and predictive factors in real-world Alzheimer's disease patients treated with lecanemab

Background Alzheimer's disease (AD) is a common progressive neurodegenerative disorder. Lecanemab, an anti-amyloid-β (Aβ) monoclonal antibody, is approved for AD treatment, but real-world efficacy and optimal PET application strategies remain incompletely defined. Objective To investigate lecanemab's Aβ clearance effic...

Z. Qiao, Xiao-Bin Zhao, Gui-Hong Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.